These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24072219)

  • 1. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
    Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
    Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Breast Cancer Res Treat; 2024 Nov; 208(2):415-427. PubMed ID: 39017815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
    J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
    BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
    Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
    Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2 and topoisomerase II as predictors of response to chemotherapy.
    Pritchard KI; Messersmith H; Elavathil L; Trudeau M; O'Malley F; Dhesy-Thind B
    J Clin Oncol; 2008 Feb; 26(5):736-44. PubMed ID: 18258981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
    Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
    Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
    Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
    Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
    Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.
    Pitroda SP; Bao R; Andrade J; Weichselbaum RR; Connell PP
    Clin Cancer Res; 2017 Aug; 23(15):4493-4500. PubMed ID: 28341751
    [No Abstract]   [Full Text] [Related]  

  • 19. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.